Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
OBJECTIVE
To undertake an economic evaluation of the options for vaccination of adolescents using meningococcal polysaccharide vaccine based on Victorian data.


METHODS
Cost-effectiveness and cost-benefit analyses of three options for vaccination were undertaken for hypothetical populations aged 15-19 years. Baseline analyses assumed a single year of programme implementation and vaccine protection of 5 years. Sensitivity analyses of key variables were performed. Outcomes included the number of people vaccinated, cases averted, life years saved and disability adjusted life years (DALY) averted. Lost earnings avoided were included as a measure of vaccination benefit in cost-benefit analyses.


RESULTS
Vaccination of people in Years 10-12 (secondary school) and first year university within a defined population with a high rate of disease was the most cost-effective option. Excluding direct cost savings and compared with no vaccination, this resulted in a discounted cost per DALY avoided of $17646 and benefits exceeding costs in discounted terms. The 'break-even' incidence rate for this option in the cost-benefit analysis was 11.9/100000.


CONCLUSIONS
Economic evidence favours the use of vaccination within well-defined populations with a high rate of disease.
Skull
S A
SA
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia. sue.skull@mh.org.au
Butler
J R
JR
D000293:Adolescent; D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000191:economics* / Q000627:therapeutic use*; D009345:Neisseria meningitidis; D014739:Victoria / Q000453:epidemiology
D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine